Molecular Tumor Grading to Improve Breast Cancer Management

AviaraDx has developed a 5-gene expression index used to stratify breast cancer patients into low or high risk of recurrence.

• MGI – allows quantitative and objective molecular assessment of tumor grade and proliferation rate.
• MGI – discriminates between tumor grades 1 and 3 and reclassifies grade 2 tumors into two distinct groups¹:
  — Low MGI – low risk of recurrence, Grade 1-like
  — High MGI – high risk of recurrence, Grade 3-like

MGI is prognostic for estrogen receptor (ER) positive patients regardless of nodal status.¹ The five genes of MGI are preferentially expressed in⁴:

• High grade > low grade tumors.
• Invasive tumors > ductal carcinoma in situ (DCIS).
• Different phases and processes of the cell cycle.

MGI is significantly associated with Pathological Complete Response (pCR) from chemotherapy⁵

• High MGI is significantly associated with a pCR in ER+ tumors. (P=0.0053)
• Approximately 20% of high MGI tumors had a pCR.
• No tumors with a low MGI (~55%) had a pCR.
• MGI indicates which tumors will have a likelihood to be either sensitive or resistant to chemotherapy.

Clinical Validations
Collaborative studies validating clinical utility of the MGI have been completed and published in peer reviewed scientific journals:

• Harvard Medical School/MGH, Boston, MA.¹

Sample and Technical Information

• Real-time RT-PCR assay.
• Compatible with formalin-fixed paraffin embedded samples.
• Patent pending.

 

View MGI Publications

Click here for Understanding MGI and Tumor Grading

 

References:
1 Ma X-J, Salunga R, Dahiya S, et al: A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res. 14(9); 2601-2608, May, 2008.
2 Cianfrocca M, Goldstein LJ: Prognostic and predictive factors in early-stage breast cancer. Oncologist, 9:606-616, 2004
3 Schnitt SJ. Traditional and newer pathologic features. J Natl Cancer Inst Monogr., 22-26, 2001
4 Whitfield ML, Sherlock G, Saldanha AJ, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell., 13:1977-2000. 2002. Also http://genome-www.stanford.edu/Human- CellCycle/Hela/index.shtml
5 Raw data from Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol., 24:4236-4244, 2006

| TOP |